Polaryx Therapeutics, Inc.
PLYX
$3.37
$0.092.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 0.84% | -- | -- | -- | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 79.71% | -- | -- | -- | |
| Operating Income | -79.71% | -- | -- | -- | |
| Income Before Tax | 70.40% | -- | -- | -- | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 70.40% | -- | -- | -- | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 70.40% | -- | -- | -- | |
| EBIT | -79.71% | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | 83.38% | -- | -- | -- | |
| Normalized Basic EPS | 83.39% | -- | -- | -- | |
| EPS Diluted | 83.38% | -- | -- | -- | |
| Normalized Diluted EPS | 83.39% | -- | -- | -- | |
| Average Basic Shares Outstanding | 32.90% | -- | -- | -- | |
| Average Diluted Shares Outstanding | 32.90% | -- | -- | -- | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |